Results 161 to 170 of about 16,064,511 (322)
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell +6 more
wiley +1 more source
Infliximab for the treatment of fistulas in patients with Crohn's disease.
D. Present +11 more
semanticscholar +1 more source
Abstract Objectives Anaemia impairs daily activities and quality of life in patients with paediatric‐onset inflammatory bowel disease (PIBD). This study aimed to investigate the prevalence of anaemia at PIBD‐diagnosis and the following 5 years. Furthermore, anaemia subtypes and the association between anaemia and disease activity were assessed over ...
Julie Rahbek Norup +3 more
wiley +1 more source
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
B. Feagan +26 more
semanticscholar +1 more source
Abstract Objective Nutritional therapy is a cornerstone for the induction of remission in pediatric Crohn's disease (CD); however, the optimal dietary strategy remains uncertain. This study aimed to compare the short‐ and long‐term therapeutic outcomes of exclusive enteral nutrition (EEN) and the Crohn's disease exclusion diet (CDED) in a large cohort ...
Danielle Pevzner +7 more
wiley +1 more source
Pharmacotherapy of Crohn's disease
Overview of the pathophysiology of Crohn's disease. The symptomatic and direct pharmacotherapy of the disease. Further studies and research trials connected to pharmacotherapy of Crohn'sáltalános orvosangolegységes ...
Olafsson, Steinar
core
Abstract Objectives To estimate the effect of attention deficit hyperactivity disorder (ADHD) and autism on the disease activity of inflammatory bowel disease (IBD) in pediatric and young patients. Methods Patients diagnosed with IBD between the ages of 6 and 24 years were identified in Danish nationwide registries 1996–2022.
Sabine Jansson +7 more
wiley +1 more source
Health Technology Assessment of Infliximab: A Rapid Review of Type 2 Studies
Background: Infliximab has been used for treatment of patients with Crohn's disease whose symptoms or developed fistula could not be eliminated by standard treatments.
Mohamadreza Mobinizadeh +6 more
doaj

